Pancreatic Cancer Research

ResearcherNational Institutes of HealthNo recent work listed

Ira H Pastan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0002-9223-0270; OpenAlex author ID A5056573254, A5111569932; NIH RePORTER profile ID 8289669. Sources: ClinicalTrials.gov.

Their work

Papers
4 (first author 0, last author 4)
Trials
1
Grants
3
Labs led
1
Collaborators
6
Papers, trials and grants by year

1998: 1 trial · 1999: none · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 2 papers, 1 grant · 2015: 1 paper · 2016: none · 2017: 1 grant · 2018: none · 2019: none · 2020: 1 paper, 1 grant

Papers 4

  1. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-19-2586↗
  2. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. Last author DOI 10.1371/journal.pone.0122462↗
  3. Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells. Last author DOI 10.1097/cji.0000000000000010↗
  4. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Last author DOI 10.1158/1535-7163.mct-14-0089-t↗

Trials 1

  1. LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors Study chair NCT00019435↗

Grants 3

  1. Clinical Trials with Immunotoxins ZIABC010020↗
  2. Growth Regulation Section ZIABC010298↗
  3. Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies ZIABC008753↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kevin Hollevoet · 3 shared papers, 2014–2015 · strength 0.18
  2. Raffit Hassan · 1 shared paper, 2020 · strength 0.10
  3. Jane B Trepel · 1 shared paper, 2020 · strength 0.10
  4. Christine C Alewine · 1 shared paper, 2020 · strength 0.10
  5. William Douglas Figg · 1 shared paper, 2020 · strength 0.10
  6. Zishuo Ian Hu · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.